AstraZeneca Combo for Type 2 Diabetes Gets Green Light in EU - Medscape
MedscapeAstraZeneca Combo for Type 2 Diabetes Gets Green Light in EUMedscapeThe European Medicines Agency (EMA) has given the green light to a fixed-dose combination of saxagliptin (Onglyza, AstraZeneca) and dapagliflozin (Forxiga/Farxiga, AstraZeneca), two oral blood glucose-lowering medicines, for the treatment of type 2 .
DPP IV Inhibitors - PR Newswire (press release)
DPP IV InhibitorsPR Newswire (press release)II-14 Table 5: Global Sales of Onglyza (Saxagliptin) Franchise by Region (2016, 2018, 2020 & 2022): Value Sales in US$ Million for US and Rest of World (includes corresponding Graph/Chart) II-15 Tradjenta (Boehringer Ingelheim) II-15 TENELIA .
AstraZeneca Gets Complete Response Letter from FDA For Potassium-Lowering Drug, Competitor Relypsa Soars ... - Sonoran Weekly Review
AstraZeneca Gets Complete Response Letter from FDA For Potassium-Lowering Drug, Competitor Relypsa Soars .
FDA warns on heart failure risk associated with Onglyza, Nesina - BioPharma Dive
MedscapeFDA warns on heart failure risk associated with Onglyza, NesinaBioPharma DiveThe FDA is adding new warnings to the labels for AstraZeneca's Onglyza (saxagliptin) and Takeda's Nesina (alogliptin) after an internal safety review found an increased risk of heart failure with the two diabetes drugs.
NICE backs freer use of SGLT2 inhibitors for diabetes - PMLiVE
NICE backs freer use of SGLT2 inhibitors for diabetesPMLiVEImportantly the recommendations put the SGLT2 inhibitors on a par with another newer class of diabetes drug - DPP-4 inhibitors such as MSD's Januvia (sitagliptin) and AstraZeneca's Onglyza (saxagliptin).